Press release
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients Inaugural Scientific Summit Prioritized
About this update from Amgen Inc.
[{"type":"text","content":"Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients \nInaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs \nTHOUSAND OAKS, Calif., Sept. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen's oncology research and development experts and world-class clinical leaders at eight research centers across the globe. As part of Amgen's mission to improve care through partnerships across the healthcare ecosystem, the network fosters academic collaboration to advance new treatment options for patients with the greatest unmet needs. The member institutions are:\n- Asan Medical Center (Seoul, South Korea)- Dana-Farber Cancer Institute (Boston)- West German Cancer Center at University Hospital Essen (Essen, Germany)- Gustave Roussy (Paris)- Memorial Sloan Kettering Cancer Center (New York)- Peter MacCallum Cancer Centre (Melbourne, Australia)- University Health Network's Princess Margaret Cancer Centre (Toronto)- Vall d'Hebron Institute of Oncology (Barcelona, Spain)\n\"We have a big goal – to make profound differences in changing the standard of cancer care – and we are committed to doing that through collaboration,\" said Jean-Charles Soria, M.D., Ph.D., senior vice president, Research and Development at Amgen. \"Through Amgen Partners of Choice, we hope to foster earlier, deeper and more frequent academic collaboration to fuel quicker progress for patients facing complex, difficult-to-treat cancers.\"\nThe network aims to create multiple collaboration channels globally with the goal of expediting the transition of new, transformational programs to leaders in the clinic. Current Amgen Partners of Choice projects are focused on select disease areas and tumor types including thoracic, gastrointestinal and genitourinary cancers.\n\"We are entering an extraordinary new era in biotechnology, a moment where both the need for innovation and our ability to innovate are expanding exponentially,\" said Professor Fabrice Barlesi, General Director of Gustave Roussy, Paris Saclay Cancer Cluster, Grand Paris. \"As a member of Amgen Partners of Choice, we look forward to collaborating closely with Amgen and other memb...